Allurion Technologies rises on initial data from weight-loss device treatment

Shares of healthcare company Allurion Technologies > rise 25% to $2.85 in aftermarket trade

Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and lean body mass increase to 68.5%

Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption

The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR

Company says all 52 patients remained adherent to the GLP-1 medication through eight months

Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company

Stock had fallen 88.5% in 2024